Back to News
Market Impact: 0.05
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
Source: PR Newswire
Healthcare & Biotech
The provided text only identifies Innovent Biologics (HKEX: 01801) as a biopharmaceutical company developing, manufacturing and commercializing medicines across oncology, cardiovascular and metabolic diseases. No specific clinical, financial, regulatory or product-development announcement is included in the article excerpt.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Street Calls of The Week
- argenx reports positive phase 3 data for autoimmune myositis drug
- Why the prognosis for healthcare stocks is uncertain ahead of Congress’ new makeup
- AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy
- J&J presents patient data on nipocalimab for Sjögren’s disease
- Rent-a-grandchild: Businesses offering companions to elderly grow in India